Coldstream Capital Management Inc. Increases Stock Position in Organon & Co. (NYSE:OGN)

Coldstream Capital Management Inc. raised its holdings in shares of Organon & Co. (NYSE:OGN) by 21.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,351 shares of the company’s stock after buying an additional 4,058 shares during the period. Coldstream Capital Management Inc.’s holdings in Organon & Co. were worth $415,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in OGN. Mercer Global Advisors Inc. ADV grew its position in Organon & Co. by 1.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after acquiring an additional 546 shares in the last quarter. Ballentine Partners LLC boosted its position in Organon & Co. by 3.0% in the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after buying an additional 552 shares during the last quarter. Sippican Capital Advisors grew its stake in shares of Organon & Co. by 4.3% during the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after acquiring an additional 627 shares in the last quarter. Commerce Bank increased its position in shares of Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after acquiring an additional 637 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Organon & Co. by 6.6% in the second quarter. Signaturefd LLC now owns 11,308 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

OGN has been the subject of a number of recent analyst reports. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and upped their price objective for the company from $18.00 to $20.00 in a research note on Friday, September 6th.

Organon & Co. Trading Down 0.3 %

Organon & Co. stock opened at $15.30 on Friday. Organon & Co. has a 1 year low of $12.62 and a 1 year high of $23.10. The firm’s 50-day moving average is $16.46 and its 200-day moving average is $19.18. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a market cap of $3.94 billion, a P/E ratio of 3.04, a PEG ratio of 0.73 and a beta of 0.75.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period last year, the company posted $0.78 earnings per share. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, equities analysts expect that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.32%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.